Alector Appoints Neil Berkley as CFO

The latest announcement is out from Alector ( (ALEC) ).

On December 10, 2025, Alector appointed Neil Berkley as Chief Financial Officer, a role he has been serving in an interim capacity since June 2025. Berkley, who will also continue as Chief Business Officer, brings over two decades of experience in biotech, having played a crucial role in advancing Alector’s strategic priorities and partnerships. His appointment is expected to support the company’s ongoing development of transformative therapies for neurodegenerative diseases.

The most recent analyst rating on (ALEC) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Alector stock, see the ALEC Stock Forecast page.

Spark’s Take on ALEC Stock

According to Spark, TipRanks’ AI Analyst, ALEC is a Underperform.

Alector’s overall stock score is heavily impacted by its poor financial performance and negative corporate events. The company’s ongoing unprofitability, bearish technical indicators, and strategic setbacks contribute to a low score. The absence of positive earnings call data and concerning valuation metrics further weigh down the stock’s attractiveness.

To see Spark’s full report on ALEC stock, click here.

More about Alector

Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the progression of neurodegenerative diseases. The company leverages genetics, immunology, and neuroscience to advance a portfolio of programs targeting conditions like Alzheimer’s, Parkinson’s, and frontotemporal dementia. Alector is also developing the Alector Brain Carrier (ABC), a proprietary platform aimed at enhancing the delivery of therapeutics across the blood-brain barrier.

Average Trading Volume: 2,707,274

Technical Sentiment Signal: Sell

Current Market Cap: $141.9M

See more insights into ALEC stock on TipRanks’ Stock Analysis page.